Pirouette is developing an auto-injector platform intended to simplify administration of life‑saving injections, including epinephrine and naloxone. The company is led by a team with backgrounds at MIT, Harvard Medical School, Harvard Business School, Clarkson University, General Electric, and NASA. Pirouette holds 21 awarded patents with additional filings underway. The company recently ran a community investment round on Wefunder and has surpassed $5 million in commitments. Management extended the round due to overwhelming demand and intends the funds to accelerate the pathway to market. The round remains open to the public for a limited time, offering an opportunity for impacted individuals and supporters to invest and own a stake.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

May 2024